1. Cell Cycle/DNA Damage
  2. DNA Alkylator/Crosslinker

Uramustine (Synonyms: Uracil mustard)

Cat. No.: HY-13544 Purity: 98.48%
Handling Instructions

Uramustine is an oral alkylating agent, effective in the treatment of lymphosarcoma, chronic lymphatic leukaemia, and thrombocythemia.

For research use only. We do not sell to patients.
Uramustine Chemical Structure

Uramustine Chemical Structure

CAS No. : 66-75-1

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 79 In-stock
5 mg USD 72 In-stock
10 mg USD 96 In-stock
50 mg USD 120 In-stock
100 mg USD 144 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References


Uramustine is an oral alkylating agent, effective in the treatment of lymphosarcoma, chronic lymphatic leukaemia, and thrombocythemia.

IC50 & Target

DNA Alkylator[1]

In Vitro

Uramustine is an oral alkylating agent, with potent antitumor activity. Uramustine inhibits human chronic myeloid leukaemia K562 cell line, with an IC50 of 5.1 μM.

Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 3.9667 mL 19.8334 mL 39.6668 mL
5 mM 0.7933 mL 3.9667 mL 7.9334 mL
10 mM 0.3967 mL 1.9833 mL 3.9667 mL
Please refer to the solubility information to select the appropriate solvent.
Cell Assay

Uramustine is dissolved in DMSO[1].

The K562 human chronic myeloid leukemia cells are maintained in RPM1 1640 medium supplemented with 10% fetal calf serum and 2 mM glutamine at 37°C in a humidified atmosphere containing 5% CO2 and are incubated with a specified dose of drug for 1 h at 37°C in the dark. The incubation is terminated by centrifugation (5 min, 300 g), and the cells are washed once with drug-free medium. Following the appropriate Uramustine treatment, the cells are transferred to 96-well microtiter plates, with 104 cells per well and 8 wells per sample. Plates are then kept in the dark at 3°C in a humidified atmosphere containing 5% CO2. The assay is based on the ability of viable cells to reduce a yellow soluble tetrazolium salt, MTT to an insoluble purple formazan precipitate. Following incubation of the plates for 4 days (to allow control cells to increase in number by 10-fold), 20 μL of a 5 mg/mL solution of MTT in phosphate-buffered saline is added to each well and the plates are further incubated for 5 h. The plates are then centrifuged for 5 min at 300 g, and the bulk of the medium is pipetted from the cell pellet, leaving 10−20 μL per well. A total of 200 μL of DMSO is added to each well, and the samples are agitated to ensure complete mixing. The optical density is then read at a wavelength of 550 nm on a plate reader, and the dose−response curve is constructed. For each curve, an IC50 value is read as the dose required to reduce the final optical density to 50% of the control value[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight








Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 29 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 98.48%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number *


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: